p53, p21, and p73 gene polymorphisms in gastric carcinoma

Hepato-Gastroenterology

Volumn 57, Issue 104, 2010, Pages 1595-1601

  Shirai, Osamu ^a   Ohmiya, Naoki ^a   Taguchi, Ayumu ^a   Nakamura, Masanao ^a   Kawashima, Hiroki ^a   Miyahara, Ryoji ^b   Itoh, Akihiro ^a   Hirooka, Yoshiki ^b   Watanabe, Osamu ^a   Ando, Takafumi ^a   Goto, Yasuyuki ^a   Hamajima, Nobuyuki ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric carcinoma; p53; Polymorphism

Indexed keywords

PROTEIN P21; PROTEIN P53; PROTEIN P73;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISTANT METASTASIS; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; STOMACH CARCINOMA;

CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79952397423     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Lane DP: Cancer. p53, guardian of the genome. Nature 1992; 358:15-16.
2. Jin S, Levine AJ: The p53 functional circuit. J Cell Sci 2001; 114:4139-4140. (Pubitemid 33138651)
3. Xie HL, Su Q, He XS, et al: Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J Gastroenterol 2004; 10(8):1125-1131. (Pubitemid 38559386)
4. Xi YG, Ding KY, Su XL, et al: p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 2004; 25(11):2201-2206.
5. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366(6456):701-704.
6. Jost CA, Marin MC, Kaelin WG, Jr: p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389(6647):191-194. (Pubitemid 27400602)
7. Lim BH, Soong R, Grieu F, et al: p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 1996; 69(3):200-204. (Pubitemid 26233299)
8. El-Omar EM, Carrington M, Chow WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404(6776):398-402. (Pubitemid 30164342)
9. Ohmiya N, Taguchi A, Mabuchi N, et al: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 24(27):4434-4440. (Pubitemid 46630981)
10. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003; 18(4):377-385. (Pubitemid 36850206)
11. Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, et al: The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 2008; 61(3):309-316.
12. Lee JM, Shun CT, Wu MT, Chen YY, et al: The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat Res 2006; 594(1-2):181-188.
13. Koushik A, Tranah GJ, Ma J, et al: p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006; 119(8):1863-1868. (Pubitemid 44356844)
14. Tommiska J, Eerola H, Heinonen M, et al: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005; 11(14):5098-5103. (Pubitemid 41003693)
15. Soulitzis N, Sourvinos G, Dokianakis DN, et al: p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002; 179(2):175-183. (Pubitemid 34215109)
16. Koushik A, Platt RW, Franco EL: p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004; 13(1):11-22. (Pubitemid 38116615)
17. Zhou Y, Li N, Zhuang W, et al: P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007; 121(7):1481-1486. (Pubitemid 47328706)
18. Hishida A, Matsuo K, Tajima K, et al: Polymorphisms of p53 Arg72Pro, p73 G4Cl4-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma 2004; 45(5):957-964. (Pubitemid 38444672)
19. Popanda O, Edler L, Waas P, et al: Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 2007; 55(1):25-34. (Pubitemid 46038874)
20. Lukas J, Groshen S, Saffari B, et al: WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 1997; 150(1):167-175. (Pubitemid 27027107)
21. Roh J, Kim M, Kim J, et al: Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett 2001; 165(1):59-62. (Pubitemid 32206658)
22. Roh JW, Kim JW, Park NH, et al: p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 2004; 93(2):499-505. (Pubitemid 38507625)
23. Chen WC, Wu HC, Hsu CD, et al: p21 gene codon 31 polymorphism is associated with bladder cancer. Urol Oncol 2002; 7(2):63-66.
24. Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90(4):809-819. (Pubitemid 27357971)
25. Hamajima N, Matsuo K, Suzuki T, et al: No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002; 181(1):81-85. (Pubitemid 34326437)
26. Niwa Y, Hamajima N, Atsuta Y, et al: Genetic poly morphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 2004; 205(1):55-60. (Pubitemid 38230139)
27. Niwa Y, Hirose K, Matsuo K, et al: Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 2005; 219(2):183-190. (Pubitemid 40269482)
28. Ohyama I, Ohmiya N, Niwa Y, et al: The association between tumour necrosis factor-alpha gene polymorphism and the susceptibility to rugal hyperplastic gastritis and gastric carcinoma. Eur J Gastroenterol Hepatol 2004; 16(7):693-700. (Pubitemid 38901639)
29. Taguchi A, Ohmiya N, Shirai K, et al: Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005; 14(11 Pt 1):2487-2493. (Pubitemid 41752706)
30. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma - 2nd Enghsh Edition. Gastric Cancer 1998; 1(1):10-24.
31. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116(6):1453-1456. (Pubitemid 29258894)
32. Li FP, Fraumeni JF, Jr., Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362.
33. Birch JM, Hartley AL, Tricker KJ, et al: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994; 54(5):1298-1304. (Pubitemid 24108072)
34. Shirai K, Ohmiya N, Taguchi A, et al: Interleukin-8 gene polymorphism associated with susceptibiUty to non-cardia gastric carcinoma with microsatellite instability. J Gastroenterol Hepatol 2006; 21(7):1129-1135.
35. Hamajima N, Saito T, Matsuo K, et al: Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000; 91(9):865-868.
36. Ohmiya N, Matsumoto S, Yamamoto H, et al: Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal cancers of the microsatellite mutator phenotype. Gene 2001; 272(1-2):301-313. (Pubitemid 32695423)
37. Niimi C, Goto H, Ohmiya N, et al: Usefulness of p53 and Ki-67 immunohistochemical analysis for preoperative diagnosis of extremely well-differentiated gastric adenocarcinoma. Am J Clin Pathol 2002; 118(5):683-692. (Pubitemid 37046312)
38. Zhang ZW, Newcomb P, Hollowood A, et al: Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003; 9(6):2151-2156. (Pubitemid 36687637)
39. Hiyama T, Tanaka S, Kitadai Y, et al: p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002; 100(3):304-308. (Pubitemid 34728988)
40. Whibley C, Pharoah PD, Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9(2):95-107.
41. Huang ZH, Hua D, Li LH, et al: Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J Cancer Res Clin Oncol 2008; 134(10):1129-1134.
42. Sullivan A, Syed N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23(19):3328-3337. (Pubitemid 38669822)
43. Nelson HH, Wilkojmen M, Marsit CJ, et al: TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005; 26(10):1770-1773. (Pubitemid 41487993)
44. Santos AM, Sousa H, Portela C, et al: TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340(1):256-262. (Pubitemid 41827674)
45. Toyama T, Zhang Z, Nishio M, et al: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007; 9(3):R34.
46. Dumont P, Leu JI, Della Pietra AC, et al: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33(3):357-365. (Pubitemid 36278852)
47. Chen JQ, Zhan WH, He YL, et al: Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol 2004; 10(6):776-782.
48. Joo M, Lee HK, Kang YK: Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis. Anticancer Res 2003; 23(2B):1581-1588. (Pubitemid 36754132)
49. Rahman-Roblick R, Roblick UJ, Hellman U, et al: p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A 2007; 104(13):5401-5406. (Pubitemid 47175692)